BioGeometry, a digital biology pioneer company that specializes in applying generative AI to protein design, recently announced a strategic partnership jointly with Sanyou Bio, a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biologic. Both parties will leverage their respective expertise in generative AI technology and practical experience from target discovery to drug Investigational New Drug (IND) application, to create a next-generation AIGC-driven antibody drug discovery platform. They will jointly promote tripartite cooperation with significant innovative drug companies or biotech firms to enhance the efficiency of new drug R&D and help pharmaceutical R&D enterprises improve their global competitiveness.

In this strategic cooperation, while introducing BioGeometry’ self-developed generative AI antibody design platform (GeoBiologics) to Sanyou, both parties will invest their respective advantageous resources and experience to establish an AI-Wet Lab integrated antibody R&D platform, leveraging BioGeometry’s leading AI dry lab platform with Sanyou’ wet lab capabilities. This collaborative effort aims to the development of more large molecule drug pipelines and the incubation of innovative projects, and to carry out further market development.

Cooperation Signing Ceremony

Sanyou has built a world-leading high-throughput, and integrated innovative antibody drug R&D platform, accumulating the world’s largest antibody library and other technological resources. The antibody library construction platform, centered on nine super-trillion antibody libraries with a total capacity of up to 10 trillion, seamlessly integrates phage display and mammalian cell protein expression technologies. Equipped with fully automated screening and integrated antibody drug R&D capabilities, it is suitable for challenging high-difficulty innovative targets and developing complex new molecules, with a focus on producing highly natural, affinity-rich, superbly developable candidates backed by the company’s extensive wet-lab and data analytics expertise.

As a leader in AI-driven protein design, BioGeometry has developed atomic-level geometric deep learning models that learn from a vast amount of data, effectively saving time and costs in antibody design, improving economic efficiency, and increasing the success rate. Moreover, BioGeometry has achieved a dry-wet lab closed-loop on its generative AI antibody discovery SaaS platform, GeoBiologics. Molecules generated or optimized through AI models are then validated and screened through high-throughput wet-lab experiments, and the experimental data are fed back into the AI model, enhancing the prediction accuracy and confidence of the AI. This iterative process of AI design and wet-lab validation can more efficiently identify functional molecules.

Source:- BioGeometry